Eli Lilly and Company (NYSE:LLY) Rating Reiterated by Cantor Fitzgerald

Eli Lilly and Company (NYSE:LLYGet Free Report)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a research report issued on Monday, Benzinga reports. They presently have a $815.00 target price on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 6.68% from the stock’s previous close.

Several other brokerages also recently weighed in on LLY. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. BMO Capital Markets upped their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Truist Financial restated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. Finally, DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a report on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $700.00.

View Our Latest Report on Eli Lilly and Company

Eli Lilly and Company Trading Up 0.4 %

Shares of Eli Lilly and Company stock opened at $763.96 on Monday. Eli Lilly and Company has a 52-week low of $342.30 and a 52-week high of $800.78. The stock’s 50-day simple moving average is $739.63 and its 200 day simple moving average is $641.00. The stock has a market capitalization of $725.88 billion, a P/E ratio of 131.72, a P/E/G ratio of 1.71 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.09 earnings per share. As a group, research analysts anticipate that Eli Lilly and Company will post 12.42 EPS for the current year.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In the last three months, insiders sold 195,055 shares of company stock valued at $125,254,657. Corporate insiders own 0.13% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently made changes to their positions in the stock. Lipe & Dalton purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the third quarter valued at $27,000. Retirement Group LLC raised its stake in Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after buying an additional 35 shares in the last quarter. Tidemark LLC acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $29,000. Finally, Core Wealth Advisors Inc. raised its stake in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read More

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.